2026-10-15T10:16:36Z https://data.mendeley.com/oai

oai:data.mendeley.com/3df2cj3v9z.2 2025-07-07T17:10:45Z

Ibrahim, Eldirdiri Fadol Ibrahim AMI-M1 Mendeley Data AML-M1 (Acute Myeloid Leukemia, French-American-British Classification M1) Definition: AML-M1 is a subtype of acute myeloid leukemia characterized by a proliferation of myeloblasts (immature white blood cells) with minimal maturation. It is classified under the FAB (French-American-British) system as M1, which means “without maturation.” Key Features: Bone marrow and blood contain ≥ 20% myeloblasts with minimal differentiation into mature cells. Myeloblasts typically lack significant granulocytic maturation beyond the blast stage. Common markers: CD13, CD33 are usually positive, HLA-DR often positive. Clinical symptoms: fatigue, anemia, infections, bleeding tendencies due to bone marrow failure. Diagnosis: Bone marrow biopsy showing ≥ 20% myeloblasts. Immunophenotyping showing expression of myeloid markers such as CD13, CD33. Cytogenetic and molecular testing to identify mutations (e.g., FLT3, NPM1) that guide prognosis and treatment. Treatment: Typically involves intensive chemotherapy aimed at inducing remission. May include consolidation chemotherapy and hematopoietic stem cell transplantation in eligible patients. Prognosis: Prognosis depends on various factors including genetic mutations, patient age, and response to treatment. AML-M1 has a variable prognosis; patients with favorable mutations have better outcomes. Hematological Cancer Chemical Treatment Science, Technology, Engineering and Mathematics Dataset doi:10.17632/3df2cj3v9z.2 oai:data.mendeley.com/3df2cj3v9z.2 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/3df2cj3v9z 2025-07-07T17:10:45Z